The Online Investor
OLI Premium
Retiree Portfolio
Stock Option Ideas
Preferred Stock Newsletter
ChartZero.com
ChartZero

Slideshow Secondary Stock Offerings

By The Online Investor Staff, updated Sun., Jun. 26, 4:49 PM

Slide #11. Global Blood Therapeutics, Inc. Secondary Offering

Company: Global Blood Therapeutics, Inc. (NASDAQ:GBT)
Date announced: 6/20/2016
Shares Offered: 6,400,000
Date of Pricing: 6/20/2016
Price Per Share: $18.75
Secondary Offering Details: Global Blood Therapeutics, Inc. (NASDAQ:GBT) (NASDAQ: GBT), a biopharmaceutical company developing novel therapeutics for the treatment of grievous blood-based disorders with significant unmet needs, today announced that it has commenced an underwritten public offering of $100 million of shares of its common stock. All shares of common stock will be offered by GBT. In addition, GBT expects to grant the underwriters a 30-day option to purchase up to an additional $15 million of shares of common stock at the public offering price, less the underwriting discount. -updated 6/20 - Global Blood Therapeutics, Inc. (NASDAQ:GBT) (NASDAQ: GBT), a biopharmaceutical company developing novel therapeutics for the treatment of grievous blood-based disorders with significant unmet needs, today announced the pricing of an underwritten public offering of 6,400,000 shares of its common stock at a public offering price of $18.75 per share, before underwriting discounts. In addition, the underwriters have a 30-day option to purchase up to an additional 960,000 shares of common stock on the same terms and conditions.

Global Bllod Therapeutics is a biopharmaceutical company dedicated to discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. Co. is developing its product candidate, GBT440, as a once-daily, oral prophylactic therapy for sickle cell disease, or SCD, and are evaluating GBT440 in both healthy subjects and SCD patients in a randomized, placebo-controlled, double-blind clinical trial that Co. characterizes as a Phase 1/2 clinical trial. SCD is a disease marked by severe pain "crises," recurrent hospitalizations, multi-organ damage, and early mortality. GBT440 targets the underlying mechanism of red blood cell sickling.

GBT SEC Filing Email Alerts Service

Open the GBT Page at The Online Investor »

Company Name:  Global Blood Therapeutics Inc
Website:  www.globalbloodtx.com
Sector:  Drugs & Pharmaceuticals
Number of ETFs Holding GBT:  14
Total Market Value Held by ETFs:  $2.63M
Total Market Capitalization:  $536.00M
% of Market Cap. Held by ETFs:  0.49%
 

Open the GBT Page at The Online Investor (in a new window) »

June 26, 2016    4:49 PM Eastern
Quotes delayed 20 minutes



Strong Buy (3.83 out of 4)
82nd percentile
(ranked higher than approx. 82% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Secondary Stock Offerings | www.TheOnlineInvestor.com | Copyright © 1998 - 2016, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.